Anhui Baker United Pharmaceutical Co., Ltd. (Baker United Pharmaceuticals) is a high-tech enterprise specializing in the research and development, production and sales of chiral antiviral drugs. Its predecessor was Anhui Baker Pharmaceutical Co., Ltd. The company has two wholly-owned subsidiaries: Anhui Baker Biopharmaceutical Co., Ltd. and Anhui Baker Pharmaceutical Operations Co., Ltd.
Baker United Pharmaceuticals currently has more than 700 employees, with R&D personnel accounting for 20% of the total number. At present, the company has total assets of RMB 600 million and a total area of ??308 acres (205,333 square meters). It has a complete industrial chain from API R&D and synthesis to preparation production and sales. At the same time, Baker United Pharmaceuticals undertakes the construction and research projects of the Chiral Drug Engineering Technology Research Center in Anhui Province, providing strong support for enterprise development.
Baker United Pharmaceuticals masters the world's leading core technology for chiral drugs, has the largest production capacity and the most complete variety of anti-hepatitis B and anti-AIDS API production bases in China, and pioneered the development of domestically produced anti-hepatitis B and anti-AIDS drugs. It is the first of its kind to end the country's long history of relying on imported antiviral drugs.
The 12th Five-Year Plan of Baker United Pharmaceuticals has clearly stated: During the 12th Five-Year Plan, in accordance with the requirements of the National Strategic Emerging Industry Development Outline, and closely focusing on the theme of the biomedical industry, the enterprise will be built into China's anti-AIDS and treatment Hepatitis B and biopharmaceutical R&D and production bases benefit patients in China and around the world and contribute to human health; the second phase of the company's API base construction project was fully launched in 2012 (including two world new molecular drug projects: multi-target treatment of diabetes, Multi-target cardiovascular disease drugs); all self-produced APIs have been submitted for approval and put into the market; the company is promoting the process of listing on the small and medium-sized board; by the end of the 12th Five-Year Plan, the company can achieve an annual output value of more than 10 billion yuan, profits and taxes of 1.5 billion yuan, and export earnings of 6 billion dollars.
The company will develop products with technological innovation, stabilize production with management innovation, and expand markets with service innovation. It will actively pass international registrations and certifications such as the US FDA on-site certification, achieve international market access, and vigorously develop the international market.
By seizing the historical opportunities for development, adhering to the corporate purpose and adhering to the corporate mission, Baker United Pharmaceuticals will eventually realize the vision of "keeping hepatitis B and AIDS away from humans".
Anhui Baker United Pharmaceutical Co., Ltd. has internationally leading chiral compound synthesis technology and is one of the leading companies in China that develops and produces high-quality anti-AIDS pharmaceuticals, APIs and intermediates. The company integrates scientific research, development and production, with its consistent purpose of technological innovation and providing high-quality medicines to mankind. The company covers a total area of ??205,128 square meters (308 acres), of which the API production base covers an area of ??110,556 square meters (166 acres); the preparation factory covers an area of ??77,256 square meters (116 acres); and the R&D center covers an area of ??17,316 square meters (26 acres).
The company has a strong R&D team and an independent R&D center, including 5 PhDs and 12 masters. R&D work is carried out under the guidance of researchers and senior engineers who receive subsidies from the State Council. The company not only has a complete quality assurance system, but also adheres to the concept of green environmental protection for many years and has established advanced sewage and waste gas treatment devices. It has completed various wastewater and waste gas recovery and treatment work with high standards and high requirements, and various emission indicators. All meet national requirements. · Lamivudine API was approved by Health Canada;
· Established active partnerships with a number of multinational pharmaceutical companies; · Lafutidine API was approved by the State Food and Drug Administration GMP certificate, certificate number: Wan J0253;
· Lamivudine API has obtained the pharmaceutical GMP certificate issued by the State Food and Drug Administration, certificate number: Wan K0276;
· Anhui Baker Biopharmaceutical Co., Ltd. successfully passed GMP certification;
· British QVT FUND LP investment fund invested US$10 million;
· Silagilan capsules passed GMP certification and was invested Market sales, registration and investment promotion worldwide. · In June 2007, Anhui Baker United Pharmaceutical Co., Ltd. was established as a joint venture with Anhui Baker Pharmaceutical Co., Ltd. with an investment of US$10 million from the British company QVT. The company continues to innovate and develop its technology and scale for antiviral and anti-HIV drugs.
· In September 2007, the company invested RMB 160 million (approximately US$23 million) to build a new API production base in Taihe Industrial Park, which was officially launched that year. · In April 2008, Anhui Baker United Pharmaceutical Co., Ltd. invested RMB 130.7 million (approximately US$19 million) to wholly acquire a biopharmaceutical company located in Hefei High-tech Industrial Development Zone, and established Anhui Baker Biopharmaceutical Co., Ltd. to develop and Produces first- and second-line pharmaceutical preparations for the treatment of hepatitis B and AIDS.
· In December 2008, the company was approved to establish Anhui Baker Pharmaceutical Operations Co., Ltd., and passed the on-site acceptance of the Provincial Food and Drug Administration in March 2009. Anhui Baker United Pharmaceutical Co., Ltd. has total assets of 510 million yuan (approximately US$75 million).